Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | MDM4 | O15151 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29792372 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL178744 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29374829 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29352017 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29768913 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL29792120 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL117964 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| SCHEMBL120511 | 1.00 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| Water SCHEMBL22070159 | 0.99 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 | |
| Water SCHEMBL31472478 | 0.99 | MDM2 (0.55) | MDM2TLR2MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4634174-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4598928-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250099596-A1 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-03-27 | — | — | US | disclosed |
| WO-2024129600-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024077006-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-4317146-A1 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023219952-A1 | MELANOCORTIN TYPE 2 RECEPTOR (MC2R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099596-A1 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | CYP51A1, CYP46A1, HSD17B11 | MDM2 874/4885TLR2 3509/4885MDM4 3290/4885 |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | MDM2 2769/4885TLR2 2449/4885MDM4 4728/4885 |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | ERBB2, EGFR, ERBB3 | MDM2 673/4885TLR2 268/4885MDM4 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.